Feasibility study on the MammoSite in early-stage breast cancer: initial experience.
The aims of this study were to evaluate the feasibility, practicality, efficacy and safety of the delivery of accelerated partial breast irradiation using the MammoSite for the boost phase. Six patients aged 53-69 years with stage T1N0, T2N0, Grade I-II invasive ductal carcinoma received 9-10 Gy prescribed at 1 cm from the MammoSite balloon surface in two fractions of 4.5-5 Gy 6 h apart. The MammoSite was inserted 20-37 days postoperatively. External beam radiation therapy to the whole breast commenced 1-5 days after accelerated partial breast irradiation. The maximum skin dose ranged from 3 to 9 Gy. The skin-cavity distance ranged from 7 to 19 mm. Local discomfort resolved as the scar healed spontaneously within 3-5 days. No Grade III or higher acute toxicity or local infection was recorded. The ease of insertion and accuracy of dosimetry makes the MammoSite suitable for use in properly selected women with early-stage breast cancer in a trial setting.
Borg
M
M
Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia. mborg@adradcentre.com.au
Yeoh
E
E
Bochner
M
M
Butters
J
J
van Doorn
T
T
Farshid
G
G
Kollias
J
J
Kotasek
D
D
Gill
G
G
Lim
A
A
Olver
I
I
Parnis
F
F
Rush
G
G
D000368:Aged; D001208:Asia; D001315:Australia; D001918:Brachytherapy / Q000379:methods*; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D002404:Catheterization; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D016896:Treatment Outcome